Table 3

- A comparison with the total number of patients with a specific tumour further classified by the type of SSTIs.

Underlying malignancy	Overall N=204^*	Abscess, n=4^{^†}	Cellulitis, n=44^{^†}	Exist site infection, n=84^{^†}	Wound infection, n=72^{^†}
Underlying malignancy	n (%)
Adenocarcinoma	3 (1.5)	0 (0.0)	1 (33.3)	0 (0.0)	2 (66.7)
Brain tumor	2 (1.0)	0 (0.0)	0 (0.0)	2 (100)	0 (0)
Breast cancer	78 (38)	2 (3)	14 (18.0)	33 (42.0)	29 (37.0)
Cervical cancer	1 (0.5)	0 (0.0)	0 (0.0)	1 (100)	0 (0.0)
Cholangiocarcinoma	2 (1.0)	0 (0.0)	0 (0)	2 (100)	0 (0.0)
Choriocarcinoma	1 (0.5)	0 (0.0)	1 (100)	0 (0.0)	0 (0.0)
Colon cancer	29 (14)	0 (0.0)	9 (31)	12 (41.0)	8 (28.0)
Rectal cancer	4 (2.0)	0 (0.0)	0 (0.0)	2 (50.0)	2 (50.0)
Endometrial carcinoma	1 (0.5)	0 (0.0)	1 (100)	0 (0.0)	0 (0.0)
Gastric cancer	3 (1.5)	0 (0.0)	1 (33.3)	2 (66.7)	0 (0.0)
Gestational trophoblastic neoplasm	4 (2.0)	0 (0.0)	1 (25.0)	3 (75)	0 (0.0)
Head and neck cancer	1 (0.5)	0 (0.0)	0 (0.0)	1 (100)	0 (0.0)
Hepatocellular carcinoma	4 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (100)
Hodgkin lymphoma	5 (2.5)	0 (0.0)	0 (0.0)	0 (0.0)	5 (100)
Leiomyosarcoma	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	1 (100)
Liver cancer	5 (2.5)	0 (0.0)	3 (60)	0 (0.0)	2 (40.0)
Lung cancer	6 (2.9)	0 (0.0)	2 (33)	3 (50.0)	1 (17.0)
Lymphoma	17 (8.3)	1 (6.0)	2 (12)	9 (53.0)	5 (29.0)
Malignant neoplasia of cervix	1 (0.5)	0 (0.0)	1 (100)	0 (0)	0 (0.0)
Neuroendocrine tumour	1 (0.5)	0 (0.0)	0 (0.0)	0 (0)	1 (100)
Oesophageal cancer	3 (1.5)	1 (33.3)	0 (0.0)	1 (33.3)	1 (33.3)
Ovarian cancer	13 (6.4)	0 (0.0)	2 (15.0)	4 (31)	7 (54.0)
Pancreatic cancer	11 (5.4)	0 (0.0)	4 (36.0)	5 (45.0)	2 (18.0)
Prostate cancer	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	1 (100)
Rectal carcinoma	2 (1.0)	0 (0.0)	1 (50.0)	0 (0.0)	1 (50)
Seminoma	4 (2.0)	0 (0.0)	1 (25.0)	3 (75.0)	0 (0.0)
Spindle cell sarcoma	1 (0.5)	0 (0.0)	0 (0.0)	1 (100)	0 (0.0)

↵* n (%): Patients with specific malignancy/total malignancy,
↵^† n (%): Patients with specific malignancy/total malignancy, SSTI: soft-tissue infections